当前位置: 首页» 科研进展» 最新论文

最新论文

CRISPR-Cas13d Exhibits Robust Antiviral Activity Against Seneca Valley Virus.Front Microbiol.2022 Feb 14;13:835040.doi: 10.3389/fmicb.2022.835040. eCollection 2022

作者:
刊物名称:
DOI:
发布时间:
摘要:

Yu-Yuan Zhang,Ming-Xia Sun,Yuexiao Lian,Tong-Yun Wang,Mei-Yu Jia,Chaoliang Leng,Meng Chen,Yuan-Zhe Bai,Fandan Meng,Xue-Hui Cai,Yan-Dong Tang


Front Microbiol.2022 Feb 14;13:835040.doi: 10.3389/fmicb.2022.835040. eCollection 2022.


Abstract

In recent years, Seneca Valley virus (SVV) as a newly identified pathogen of porcine vesicular disease spread quickly and has posed a potential threat to the swine industry in several countries resulting in economic losses. Considering the evolution of SVV, attention should be given to controlling SVV epidemics. So far there are no commercial vaccines or drugs available to combat SVV. Therefore, development of strategies for preventing and controlling SVV infection should be taken into account. In the current study, we evaluated whether the CRISPR-Cas13d system could be used as a powerful tool against SVV infection. Besides, selected crRNAs showed different capacity against SVV infection. Our study suggests the CRISPR-Cas13d system significantly inhibited SVV replication and exhibited potent anti-SVV activity. This knowledge may provide a novel alternative strategy to control epidemics of SVV in the future.


Keywords: CRISPR-Cas13d; CasRx; SVV; antiviral; virus.

Copyright © 2022 Zhang, Sun, Lian, Wang, Jia, Leng, Chen, Bai, Meng, Cai and Tang.


上一篇:The Detection of  Toxoplasma gondii  in Wild Rats (  Rattus norvegicus ) on Mink Farms in Shandong Province, Eastern China.Vector Borne Zoonotic Dis.2022 Mar 3.doi: 10.1089/vbz.2021.0087
下一篇:Immunogenicity of a recombinant VSV-Vectored SARS-CoV vaccine induced robust immunity in rhesus monkeys after single-dose immunization.Virol Sin.2022 Jan 12;S1995-820X(22)00002-5.doi: 10.1016/j.virs.2022.01.002
扫一扫 关注我
网站首页 联系我们
TOP